Ziopharm Oncology Inc. (NASDAQ:ZIOP) shares dropped 2% during mid-day trading on Thursday . The stock traded as low as $5.26 and last traded at $5.31, with a volume of 682,984 shares. The stock had previously closed at $5.42.

ZIOP has been the subject of a number of analyst reports. Wells Fargo & Co. upgraded Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a report on Wednesday, August 10th. Zacks Investment Research upgraded Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a report on Tuesday, August 16th. Griffin Securities restated a “buy” rating and set a $21.00 target price on shares of Ziopharm Oncology in a report on Monday, August 15th. Raymond James Financial Inc. initiated coverage on Ziopharm Oncology in a report on Thursday, June 2nd. They set a “market perform” rating for the company. Finally, Mizuho restated a “neutral” rating and set a $5.00 target price (down previously from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.75.

The firm has a 50 day moving average price of $5.26 and a 200-day moving average price of $6.76. The company’s market capitalization is $686.41 million.

Ziopharm Oncology (NASDAQ:ZIOP) last released its earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.90. During the same quarter last year, the business earned ($0.11) earnings per share. The business had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.52 million. Ziopharm Oncology’s quarterly revenue was up 525.0% on a year-over-year basis. Equities research analysts forecast that Ziopharm Oncology Inc. will post ($1.34) EPS for the current year.

A hedge fund recently raised its stake in Ziopharm Oncology stock. California Public Employees Retirement System boosted its stake in shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) by 567.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 307,366 shares of the biotechnology company’s stock after buying an additional 261,300 shares during the period. California Public Employees Retirement System owned about 0.24% of Ziopharm Oncology worth $2,554,000 as of its most recent filing with the SEC.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.